Abstract
Influenza virus can cause epidemics and pandemics of flu. A highly variable virus genome is responsible for the existence of different viral strains and acquired resistance to antiviral drugs. Today, only one class of therapeutics, neuraminidase inhibitors, is efficient and proved for influenza prophylaxis and treatment; whereas M2 protein inhibitors became inefficient due to evolving drug resistance. Therefore, there is an urgent need for the development of novel therapeutics.
Aptamers are promising molecular recognition elements of high specificity and low toxicity, but only a few of them are under development as therapeutics. After selection of primary aptamers, there are sophisticated steps of further adjustments to the target and meeting requirements for therapeutics.
In the last decade, dozens of DNA and RNA aptamers to various influenza types have been selected, but no comparative analyses have been performed yet. Most of aptamers were selected to hemagglutinin, a viral surface protein, which supports the first stages of virus invasion into the host cell.
In the review, all available data on aptamers to hemagglutinin are analyzed. Aptamer specificity and affinity are discussed, as well as examples of aptamer applications for virus detection and virus infection inhibition. In summary, aptamers can be selected for hemagglutinin recognition, aptamers to hemagglutinin can recognize viruses with different specificity, and some aptamers can neutralize virus in vitro, ex vivo and in vivo. Special sections of the review are dedicated to the original structural analyses. Some structural similarities among different aptamers have been revealed suggesting involvement into the target recognition.
Keywords: Antivirals, aptamer, hemagglutinin, influenza.
Current Pharmaceutical Design
Title:Aptamers to Hemagglutinin: A Novel Tool for Influenza Virus Recognition and Neutralization
Volume: 22 Issue: 31
Author(s): Elena Zavyalova and Alexey Kopylov
Affiliation:
Keywords: Antivirals, aptamer, hemagglutinin, influenza.
Abstract: Influenza virus can cause epidemics and pandemics of flu. A highly variable virus genome is responsible for the existence of different viral strains and acquired resistance to antiviral drugs. Today, only one class of therapeutics, neuraminidase inhibitors, is efficient and proved for influenza prophylaxis and treatment; whereas M2 protein inhibitors became inefficient due to evolving drug resistance. Therefore, there is an urgent need for the development of novel therapeutics.
Aptamers are promising molecular recognition elements of high specificity and low toxicity, but only a few of them are under development as therapeutics. After selection of primary aptamers, there are sophisticated steps of further adjustments to the target and meeting requirements for therapeutics.
In the last decade, dozens of DNA and RNA aptamers to various influenza types have been selected, but no comparative analyses have been performed yet. Most of aptamers were selected to hemagglutinin, a viral surface protein, which supports the first stages of virus invasion into the host cell.
In the review, all available data on aptamers to hemagglutinin are analyzed. Aptamer specificity and affinity are discussed, as well as examples of aptamer applications for virus detection and virus infection inhibition. In summary, aptamers can be selected for hemagglutinin recognition, aptamers to hemagglutinin can recognize viruses with different specificity, and some aptamers can neutralize virus in vitro, ex vivo and in vivo. Special sections of the review are dedicated to the original structural analyses. Some structural similarities among different aptamers have been revealed suggesting involvement into the target recognition.
Export Options
About this article
Cite this article as:
Zavyalova Elena and Kopylov Alexey, Aptamers to Hemagglutinin: A Novel Tool for Influenza Virus Recognition and Neutralization, Current Pharmaceutical Design 2016; 22 (31) . https://dx.doi.org/10.2174/1381612822666160203142513
DOI https://dx.doi.org/10.2174/1381612822666160203142513 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A synopsis on the linkage between age-related dementias and vascular disorders
CNS & Neurological Disorders - Drug Targets Bacteria and Bacterial Toxins as Therapeutic Agents for Solid Tumors
Current Cancer Drug Targets The Secretin/Pituitary Adenylate Cyclase-Activating Polypeptide/ Vasoactive Intestinal Polypeptide Superfamily in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Post-Translational Modifications of PTEN and their Potential Therapeutic Implications
Current Cancer Drug Targets Aminophosphonic Acids of Potential Medical Importance
Current Medicinal Chemistry - Anti-Cancer Agents High-Density Lipoprotein: Key Molecule in Cholesterol Efflux and the Prevention of Atherosclerosis
Current Pharmaceutical Design Downregulation of miRNA-14669 Reverses Vincristine Resistance in Colorectal Cancer Cells through PI3K/AKT Signaling Pathway
Recent Patents on Anti-Cancer Drug Discovery Advances and Challenges in the Development of Therapeutic DNA Vaccines Against Hepatitis B Virus Infection
Current Gene Therapy Aldose Reductase, Still a Compelling Target for Diabetic Neuropathy
Current Drug Targets Assessment of Signal Peptides to Optimize Interleukin 2 (IL-2) Folding and Expression
Current Proteomics The Role of Physical Exercise and Omega-3 Fatty Acids in Depressive Illness in the Elderly
Current Neuropharmacology GM-CSF and Dendritic Cells in Allergic Airway Inflammation: Basic Mechanisms and Prospects for Therapeutic Intervention
Current Drug Targets - Inflammation & Allergy Autoimmunity and Celiac Disease
Mini-Reviews in Medicinal Chemistry Biologic Agents in the Treatment of Rheumatoid Arthritis
Current Pharmaceutical Biotechnology Meet the Section Editor
Current Neuropharmacology The Function of LncRNA FTX in Several Common Cancers
Current Pharmaceutical Design The Role of Natural Killer T Cells in Acute Kidney Injury: Angel or Evil?
Current Protein & Peptide Science Toxicological Profile of Therapeutic Nanodelivery Systems
Current Drug Metabolism Critical Roles for Bradykinin and Prostanoids in Acute Inflammatory Reactions: A Search Using Experimental Animal Models
Current Drug Targets - Inflammation & Allergy Ameliorative Effects of GW1929, a Nonthiazolidinedione PPARγ Agonist,on Inflammation and Apoptosis in Focal Cerebral Ischemic-Reperfusion Injury
Current Neurovascular Research